Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: Frequent transmission by virally inactivated clotting factor concentrates

Transfusion

Volumn 52, Issue 7, 2012, Pages 1482-1489

  Sharp, Colin P ^a   Lail, Alice ^a   Donfield, Sharyne ^a   Gomperts, Edward D ^a   Simmonds, Peter ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; IMMUNOGLOBULIN M;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE DURATION; DISEASE EXACERBATION; HEMOPHILIA; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; PARVOVIRUS; PARVOVIRUS 4; PARVOVIRUS INFECTION; RASH; SCHOOL CHILD; SEROCONVERSION; SEROPREVALENCE; TREATMENT DURATION; VIREMIA; VIRUS TRANSMISSION;

ADOLESCENT; ANTIBODIES, VIRAL; BLOOD COAGULATION FACTORS; CHILD; FEMALE; FOLLOW-UP STUDIES; HEMOPHILIA A; HUMANS; MALE; PARECHOVIRUS; PICORNAVIRIDAE INFECTIONS; RETROSPECTIVE STUDIES; VIRUS INACTIVATION;

EID: 84863799402     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03420.x     Document Type: Article

References (28)

1. Jones MS, Kapoor A, Lukashov VV, Simmonds P, Hecht F, Delwart E,. New DNA viruses identified in patients with acute viral infection syndrome. J Virol 2005; 79: 8230-6.
2. Lau SK, Woo PC, Tse H, Fu CT, Au WK, Chen XC, Tsoi HW, Tsang TH, Chan JS, Tsang DN, Li KS, Tse CW, Ng TK, Tsang OT, Zheng BJ, Tam S, Chan KH, Zhou B, Yuen KY,. Identification of novel porcine and bovine parvoviruses closely related to human parvovirus 4. J Gen Virol 2008; 89: 1840-8.
3. Allander T, Jartti T, Gupta S, Niesters HG, Lehtinen P, Osterback R, Vuorinen T, Waris M, Bjerkner A, Tiveljung-Lindell A, van den Hoogen BG, Hyypiä T, Ruuskanen O,. Human bocavirus and acute wheezing in children. Clin Infect Dis 2007; 44: 904-10.
4. Kapoor A, Simmonds P, Slikas E, Li L, Bodhidatta L, Sethabutr O, Triki H, Bahri O, Oderinde BS, Baba MM, Bukbuk DN, Besser J, Bartkus J, Delwart E,. Human bocaviruses are highly diverse, dispersed, recombination prone, and prevalent in enteric infections. J Infect Dis 2010; 201: 1633-43.
5. Arthur JL, Higgins GD, Davidson GP, Givney RC, Ratcliff RM,. A novel bocavirus associated with acute gastroenteritis in Australian children. PLoS Pathog 2009; 5: e1000391.
6. Soderlund-Venermo M, Hokynar K, Nieminen J, Rautakorpi H, Hedman K,. Persistence of human parvovirus B19 in human tissues. Pathol Biol (Paris) 2002; 50: 307-16.
7. Norja P, Hokynar K, Aaltonen LM, Chen R, Ranki A, Partio EK, Kiviluoto O, Davidkin I, Leivo T, Eis-Hübinger AM, Schneider B, Fischer HP, Tolba R, Vapalahti O, Vaheri A, Söderlund-Venermo M, Hedman K,. Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue. Proc Natl Acad Sci U S A 2006; 103: 7450-3.
8. Isa A, Kasprowicz V, Norbeck O, Loughry A, Jeffery K, Broliden K, Klenerman P, Tolfvenstam T, Bowness P,. Prolonged activation of virus-specific CD8+T cells after acute B19 infection. PLoS Med 2005; 2: e343.
9. Longhi E, Bestetti G, Acquaviva V, Foschi A, Piolini R, Meroni L, Magni C, Antinori S, Parravicini C, Corbellino M,. Human parvovirus 4 in the bone marrow of Italian patients with AIDS. AIDS 2007; 21: 1481-3.
10. Schneider B, Fryer JF, Reber U, Fischer HP, Tolba RH, Baylis SA, Eis-Hübinger AM,. Persistence of novel human parvovirus PARV4 in liver tissue of adults. J Med Virol 2008; 80: 345-51.
11. Manning A, Willey SJ, Bell JE, Simmonds P,. Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human parvoviruses PARV4 and human bocavirus. J Infect Dis 2007; 195: 1345-552.
12. Simmonds P, Manning A, Kenneil R, Carnie FW, Bell JE,. Parenteral transmission of the novel human parvovirus, PARV4. Emerg Infect Dis 2007; 13: 1386-8.
13. Sharp CP, Lail A, Donfield S, Simmons R, Leen C, Klenerman P, Delwart E, Gomperts ED, Simmonds P,. High frequencies of exposure to the novel human parvovirus, PARV4 in haemophiliacs and injecting drug users detected by a serological assay for PARV4 antibodies. J Infect Dis 2009; 200: 1119-25.
14. Panning M, Kobbe R, Vollbach S, Drexler JF, Adjei S, Adjei O, Drosten C, May J, Eis-Hubinger AM,. Frequent detection of novel human parvovirus 4 genotype 3 in infants, Ghana. Emerg Infect Dis 2010; 16: 1143-6.
15. Sharp CP, Vermeulen M, Nebie Y, Djoko CF, LeBreton M, Tamoufe U, Rimoin AW, Kayembe PK, Carr JK, Servant-Delmas A, Laperche S, Harrison GL, Pybus OG, Delwart E, Wolfe ND, Saville A, Lefrère JJ, Simmonds P,. Changing epidemiology of human parvovirus 4 infection in sub-Saharan Africa. Emerg Infect Dis 2010; 16: 1605-7.
16. Benjamin L, Lewthwaite P, Vasanthapuram R, Zhao G, Sharp CP, Simmonds P, Wang D, Solomon T,. Human parvovirus 4 (PARV4) causes encephalitis in children in Southern India. Emerg Infect Dis 2011; 17: 1484-7.
17. Hilgartner MW, Donfield SM, Willoughby A, Contant CF Jr, Evatt BL, Gomperts ED, Hoots WK, Jason J, Loveland KA, McKinlay SM, Stehbens JA,. Hemophilia growth and development study. Design, methods, and entry data. Am J Pediatr Hematol Oncol 1993; 15: 208-18.
18. Reed LJ, Muench HA,. Simple method of estimating fifty per cent endpoints. Am J Hyg 1938; 27: 493-7.
19. Lahtinen A, Kivela P, Hedman L, Kumar A, Kantele A, Lappalainen M, Liitsola K, Ristola M, Delwart E, Sharp C, Simmonds P, Söderlund-Venermo M, Hedman K,. Serodiagnosis of primary infections with human parvovirus 4, Finland. Emerg Infect Dis 2011; 17: 79-82.
20. Soderlund M, Brown CS, Spaan WJ, Hedman L, Hedman K,. Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19. J Infect Dis 1995; 172: 1431-6.
21. Scharrer I, Becker T,. Products used to treat hemophilia: evolution of treatment for hemophilia A and B. In:, Lee CA, Berntorp E, Hoots WK, editors. Textbook of hemophilia. Oxford: Blackwell Publishing Ltd; 2005. p. 131-5.
22. Blumel J, Schmidt I, Effenberger W, Seitz H, Willkommen H, Brackmann HH, Löwer J, Eis-Hübinger AM,. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion 2002; 42: 1473-81.
23. Schwarz TF, Serke S, von Brunn A, Hottenträger B, Huhn D, Deinhardt F, Roggendorf M,. Heat stability of parvovirus B19: kinetics of inactivation. Zentralbl Bakteriol 1992; 277: 219-23.
24. Tabor E, Epstein JS,. NAT screening of blood and plasma donations: evolution of technology and regulatory policy. Transfusion 2002; 42: 1230-7.
25. Schneider B, Fryer JF, Oldenburg J, Brackmann HH, Baylis SA, Eis-Hubinger AM,. Frequency of contamination of coagulation factor concentrates with novel human parvovirus PARV4. Haemophilia 2008; 14: 978-86.
26. Fryer JF, Hubbard AR, Baylis SA,. Human parvovirus PARV4 in clotting factor VIII concentrates. Vox Sang 2007; 93: 341-7.
27. Modrow S, Wenzel JJ, Schimanski S, Schwarzbeck J, Rothe U, Oldenburg J, Jilg W, Eis-Hübinger AM,. Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates. Vox Sang 2011; 100: 351-8.
28. Doyle S, Corcoran A,. The immune response to parvovirus B19 exposure in previously seronegative and seropositive individuals. J Infect Dis 2006; 194: 154-8.